Navigation Links
Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
Date:11/13/2008

oche, and Sanofi-Aventis, many key topics were covered, including:

-- Understand Product Launch Evaluation Process

-- Determine Role of Forecasting in Evaluating Success

-- Identify Key Performance Measures Used

-- Review Importance of Specific Launch Evaluation Performance Measures

-- Describe Process and Timetable for Recalibration of Launch Targets

For more information on this study or the Best Practice Database, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. Interested parties may sign-up for a customized tour of the database via the following URL: http://www3.best-in-class.com/dw212.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Best Practice Database Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development
2. MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology
3. Netsmart Technologies Releases Version 7.5 Of Helper™ Practice Management Software
4. Netsmart Technologies Releases Version 7.5 of Helper(TM) Practice Management Software
5. Ski Safety and Medical Experts, Victims of Snow Sport Tragedies and Consumers Shed Light on Questionable Safety Practices of California Ski Resorts
6. URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards
7. Best Minds, Best Practices in Medicine Conference on Nov. 11
8. In These Stressful, Budget-Busting Times, Its Wise to Invest in a Home Yoga Practice, Says Natural Solutions Magazine
9. Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress
10. Animal Dermatology Clinic Announces Today the Grand Opening of a State of the Art Veterinary Specialty Practice in Pasadena, California
11. IPC The Hospitalist Company Acquires Phoenix Area Practice
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14 2009 56735 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 2Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 3MDS Reports Third Quarter 2009 Financial Results 56733 1MDS Reports Third Quarter 2009 Financial Results 56733 2MDS Reports Third Quarter 2009 Financial Results 56733 3MDS Reports Third Quarter 2009 Financial Results 56733 4MDS Reports Third Quarter 2009 Financial Results 56733 5MDS Reports Third Quarter 2009 Financial Results 56733 6MDS Reports Third Quarter 2009 Financial Results 56733 7MDS Reports Third Quarter 2009 Financial Results 56733 8MDS Reports Third Quarter 2009 Financial Results 56733 9MDS Reports Third Quarter 2009 Financial Results 56733 10MDS Reports Third Quarter 2009 Financial Results 56733 11MDS Reports Third Quarter 2009 Financial Results 56733 12MDS Reports Third Quarter 2009 Financial Results 56733 13MDS Reports Third Quarter 2009 Financial Results 56733 14MDS Reports Third Quarter 2009 Financial Results 56733 15MDS Reports Third Quarter 2009 Financial Results 56733 16MDS Reports Third Quarter 2009 Financial Results 56733 17MDS Reports Third Quarter 2009 Financial Results 56733 18MDS Reports Third Quarter 2009 Financial Results 56733 19MDS Reports Third Quarter 2009 Financial Results 56733 20MDS Reports Third Quarter 2009 Financial Results 56733 21MDS Reports Third Quarter 2009 Financial Results 56733 22MDS Reports Third Quarter 2009 Financial Results 56733 23
Other Medicine Technology:NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8